Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-03
2005-05-03
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06887886
ABSTRACT:
The present invention is concerned with pharmaceutical compositions comprising a mixture of amlodipine enantiomers, which compositions have both anti-hypertensive and additional cardiovascular properties derived respectively from their calcium channel-blocking activity and their ability to release vascular nitric oxide (NO).
REFERENCES:
patent: 5438145 (1995-08-01), Furlan et al.
patent: 5750707 (1998-05-01), Spargo
patent: 6046338 (2000-04-01), Spargo
patent: 6080761 (2000-06-01), Chahwala et al.
patent: 6333342 (2001-12-01), Foster
patent: 0754043 (1994-10-01), None
Budavari et al., The Merck Index, Twelfth Edition (1996), pp. 86 and 87, abstract no. 516.*
J. Med Chem 29 1696 (1986), Arrowsmith, et al.
J Med Chem 35 3341-3344 (1992), Goldmann et al.
Kidney International 49 S2-S5 (1996), Igarro.
Amer J. Cardiol 73 A10-A17 (1994), D. N. Abernethy et al.
Circ Res 86 270 (2000), H. Tada et al.
J. Cardiovasc Pharmacol 35 195-202 (2000), Zhang, et al.
Circulation 97 576 (1998), Zhang and Hintze.
Am J. Cardioll 83 92H (1999), Mital et al).
J. Cardiovasc Pharmacol, vol. 12 (Suppl. 6), 1988.
Chahwala Suresh Babubhai
Dodd Michael George
Humphrey Michael John
Pfizer Inc.
Scully Scott Murphy & Presser
Weddington Kevin E.
LandOfFree
Therapeutic compositions comprising excess enantiomer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions comprising excess enantiomer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions comprising excess enantiomer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464169